(19)
(11) EP 4 561 624 A1

(12)

(43) Date of publication:
04.06.2025 Bulletin 2025/23

(21) Application number: 23847474.6

(22) Date of filing: 24.07.2023
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 35/00(2006.01)
C07K 16/30(2006.01)
 A61K 47/68(2017.01)
C07K 16/28(2006.01)
C07K 16/46(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07K 16/2803; A61K 2039/505; A61K 2039/507; C07K 16/2818; C07K 2317/24; A61K 47/68031; A61K 47/6849; A61K 47/6861
(86) International application number:
PCT/US2023/070812
(87) International publication number:
WO 2024/026253 (01.02.2024 Gazette 2024/05)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 25.07.2022 US 202263392067 P
31.08.2022 US 202263402830 P
24.05.2023 US 202363504183 P

(71) Applicants:
  • Agensys, Inc.
    Northbrook, IL 60062 (US)
  • Seagen Inc.
    Bothell, WA 98021 (US)
  • Merck Sharp & Dohme LLC
    Rahway, New Jersey 07065 (US)

(72) Inventors:
  • CARRET, Anne-Sophie
    Bothell, WA 98021 (US)
  • ABIDOYE, Oyewale, O.
    Bothell, WA 98021 (US)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Gewürzmühlstraße 11
80538 München
80538 München (DE)

   


(54) METHODS FOR TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND 191P4D12 PROTEINS IN COMBINATION WITH PEMBROLIZUMAB